Currently Dr. Dijie Liu is a principal research scientist at the Viewpoint Molecular Targeting Inc., IA USA. After receiving the doctorate diploma in the field of veterinary pharmacology and toxicology in 2000, Dr. Liu has had extensive trainings in multiple disciplines of non-viral gene delivery, molecular biology, nuclear medicine and preclinical evaluation of peptide-based radiopharmaceuticals for molecular imaging and radionuclide therapy of cancers in the University of Iowa and University of Missouri-Columbia. She has published over 30 research articles, book chapters and review papers in prestigious peer-reviewed journals. She is competent in multiple in vivo and in vitro studies including radiochemical synthesis, radioactive or non-radioactive drug pharmacokinetics, biodistribution, mice survival and non-survival surgeries, toxicology and therapy studies, molecular biology tests, development and evaluation of peptide-based radiopharmaceuticals for cancer imaging and therapy proposed for this study. She once served as the technical director of the Theranostic Radiopharmaceutical Manufacturing Facility at the University of Iowa manufacturing GMP radiopharmaceuticals for clinical trials and providing CMC (Chemistry Manufacture Control) documentation for IND application before joining Viewpoint Molecular Targeting Inc in 2021. Her current scope of research is to validate new biomarker for preclinical evaluation of alpha-particle targeted radionuclide therapy.